Refine by
Bioscience Articles & Analysis
240 news found
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is excited to announce the launch of its new Immune System Tissue Microarrays for the scientific community to study the complex interactions of the immune system in various tissues. ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, is pleased to announce the launch of its new line of Circulatory System Tissue Microarrays to the scientific community. ...
CanaQuest Medical Corp (“CanaQuest” or the “Company”) (OTC: CANQF), is pleased to announce strategic additions to its executive team with expertise in conducting clinical trials and US FDA drug approval success. The team plans to effectively navigate the regulatory approval process for Drug Candidate, CQ-001 (cannabidiol + proprietary API composition), to treat rare ...
ExcellGene SA, a leading Swiss biotech service provider specializing in mammalian cell line development for more than two decades, proudly announces its strategic collaboration with Cytovance Biologics, a renowned Contract Development and Manufacturing Organization (CDMO) based in the USA. As CHO (Chinese Hamster Ovary) and HEK (Human Embryonic Kidney) cells are the most well-suited mammalian ...
According to a recent study published in the Journal of Macromolecular Bioscience, the hydrogel microneedle patch could effectively deliver a variety of drugs, including small molecules and bioactive compounds, with improved efficiency and precision. ...
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. ...
For more information on metabolic research solutions or other pathways, please visit CD BioSciences at https://www.cd-biosciences.com/diabetes-metabolism.html. About CD BioSciences CD BioSciences is a trusted research product supplier and CRO based in New York. With high-quality reagents and comprehensive services, CD BioSciences ...
CD Bioscience has a professional team and advanced imaging equipment to provide customers with a wide range of 3D imaging services. ...
In addition, he serves on the boards of privately held Regenity Biosciences and Cerebral Therapuetics. “We are thrilled to welcome Tim Scannell as the Chair of our Board of Directors. ...
Lesnick held various executive roles at Spruce Biosciences, QED Therapeutics, Cascadian Therapeutics and Shionogi, Inc., among others, where he focused heavily on regulatory affairs and quality assurance, successfully progressing numerous clinical programs through to U.S. ...
Given the strong commitment from Belgium and the European Union towards supporting regional production autonomy in the region, and the fact that the mRNA Technology Transfer Program co-led by the World Health Organization (WHO) and Medicines Patent Pool (MPP), is at the epicenter of this global effort, the Royal delegation made it a point to include a visit to Afrigen as part of their stay. ...
ByeTheRNA
The Microplate Reader Company – and InvivoSciences, Inc. – a leader in stem cell tissue engineering providing a novel solution in first-in-class drug discovery – announced today a strategic collaboration to market the time-dependent fluorescent assessment of engineered 3D heart tissues using advanced microplate reader technologies. Employing an automated system, 3D heart ...
The antibody was transferred to Aulos Bioscience, a Biolojic spinoff that is now conducting clinical trials in Australia and is currently recruiting patients, with hopes of reporting interim data later this year. ...
Dr. Ali Tinazli's post at the Forbes magazine about "History Of Health Technologies And Meaningful Change In The Era Of Health 4.0" The medicine in ancient Egypt is some of the oldest in history. Although rudimentary, it was already highly personalized and with exclusive access. During the Renaissance—one of the most remarkable ages of humankind—medicine ...
He has held leadership and senior roles at Novartis, GE Healthcare, Quest Diagnostics, Tethys Bioscience and the US Department of Energy. About Juvena Therapeutics Juvena Therapeutics is a biotech company accelerating the development of regenerative therapeutics by unlocking the therapeutic potential of secreted proteins. ...
In 2009, as a graduate student at the University of Wisconsin-Madison, Chorom Pak was part of a group of researchers working to understand how sensitive patients’ cells were to certain therapies for blood cancers, such as multiple myeloma. The group, which also included UW-Madison professors Shigeki Miyamoto and David Beebe, and postdoctoral fellow Edmond Young, would receive ...
At the end of the 19th century, the German scientist Paul Ehrlich began to realize that certain chemicals could have highly specific effects on certain diseases. He began to write about the possibility that a drug could act like a magische kugel—magic bullet—that killed only the organism causing disease, and nothing else. Today, scientists are amassing a new arsenal of ...
A startup team from the University of Wisconsin that moved to San Diego in January to advance their technology for optimizing treatment regimens for cancer patients won the audience vote for best pitch at the EvoNexus Spring Demo Day last week. Lynx Biosciences founder and CEO Chorom Pak said her startup has developed microfluidic technology that uses live cancer ...
The strategic collaboration with Mammoth Biosciences, Inc., with its groundbreaking gene-editing technology as a key enabling technology as well as a stand-alone therapeutic modality, will significantly enhance Bayer’s efforts to develop transformative therapies. ...
ByBayer AG
Lumen Bioscience — a clinical stage biopharmaceutical company developing biologic drugs for highly prevalent diseases — announced today preliminary results from a Biomedical Advanced Research and Development Authority (BARDA)-supported effort to develop an intranasal formulation of its drug candidate, LMN-301. ...